Physician profile
Danielle Mondello
NPI 1265192058
$2,055.50
in general payments reported to CMS, 2019-2025
24 companies · $377 in 2025
The $377 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $440 · 2023: $563 · 2024: $676 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,525 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,525.32 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $359.94 | 2022-2025 | Ilumya, Winlevi |
| E.R. Squibb & Sons, L.L.C. | $217.55 | 2022-2024 | Sotyktu |
| Lilly USA, LLC | $215.49 | 2022-2024 | Olumiant, Taltz |
| Galderma Laboratories, L.P. | $151.95 | 2023-2025 | Aklief, Nemluvio, Epsolay |
| Abbvie INC. | $120.32 | 2023-2024 | |
| Leo Pharma INC. | $101.75 | 2023-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $101.26 | 2022-2024 | |
| Incyte Corporation | $98.57 | 2022-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $84.04 | 2023 | |
| Arcutis Biotherapeutics, INC. | $77.22 | 2024-2025 | Zoryve |
| Botanix Sb INC | $68.56 | 2025 | Sofdra |
| Dermavant Sciences, INC. | $63.98 | 2022-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $61.82 | 2022-2023 | Dupixent |
| Pfizer INC. | $61.69 | 2025 | |
| Mayne Pharma Commercial LLC | $57.03 | 2023-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Helsinn Therapeutics (U.S.), INC. | $39.02 | 2023-2024 | Valchlor |
| Amgen INC. | $30.52 | 2022-2023 | Otezla |
| Almirall LLC | $29.27 | 2023-2025 | Klisyri, Seysara |
| Strata Skin Sciences, INC. | $25.21 | 2025 | Xtrac |
| Kerecis Limited | $24.07 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Organon LLC | $18.38 | 2025 | Vtama |
| Ucb, INC. | $18.09 | 2025 | Bimzelx |
| Verrica Pharmaceuticals INC. | $17.00 | 2024 | Ycanth |
| Paratek Pharmaceuticals, INC. | $12.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Mondello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.